Edwards Lifesciences Corp (NYSE:EW) Shares Sold by Rosenbaum Jay D.

Rosenbaum Jay D. reduced its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 6.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,160 shares of the medical research company’s stock after selling 627 shares during the period. Edwards Lifesciences comprises about 3.2% of Rosenbaum Jay D.’s investment portfolio, making the stock its 7th largest holding. Rosenbaum Jay D.’s holdings in Edwards Lifesciences were worth $1,692,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in Edwards Lifesciences by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 601,150 shares of the medical research company’s stock valued at $92,071,000 after purchasing an additional 22,354 shares during the last quarter. Geode Capital Management LLC raised its position in Edwards Lifesciences by 7.4% in the 4th quarter. Geode Capital Management LLC now owns 2,942,494 shares of the medical research company’s stock valued at $449,976,000 after purchasing an additional 202,248 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in Edwards Lifesciences in the 1st quarter valued at $843,000. First Manhattan Co. raised its position in Edwards Lifesciences by 630.3% in the 1st quarter. First Manhattan Co. now owns 2,337 shares of the medical research company’s stock valued at $447,000 after purchasing an additional 2,017 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Edwards Lifesciences in the 1st quarter valued at $296,000. 82.43% of the stock is owned by institutional investors.

Edwards Lifesciences stock traded up $3.30 during trading hours on Thursday, reaching $216.81. 25,008 shares of the stock were exchanged, compared to its average volume of 1,186,828. The stock has a market capitalization of $44.90 billion, a PE ratio of 45.96, a P/E/G ratio of 2.72 and a beta of 0.87. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.48 and a current ratio of 3.38. Edwards Lifesciences Corp has a 52-week low of $134.53 and a 52-week high of $219.71. The company’s 50 day moving average price is $200.64.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 EPS for the quarter, topping the Zacks’ consensus estimate of $1.33 by $0.05. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. Edwards Lifesciences’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.24 EPS. Equities research analysts anticipate that Edwards Lifesciences Corp will post 5.34 earnings per share for the current fiscal year.

In other news, VP Donald E. Bobo, Jr. sold 5,369 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $216.26, for a total transaction of $1,161,099.94. Following the transaction, the vice president now directly owns 26,082 shares of the company’s stock, valued at approximately $5,640,493.32. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Michael A. Mussallem sold 22,850 shares of the company’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $184.27, for a total transaction of $4,210,569.50. Following the transaction, the chief executive officer now directly owns 95,770 shares in the company, valued at $17,647,537.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 142,948 shares of company stock worth $27,936,332. Corporate insiders own 1.63% of the company’s stock.

Several research firms recently commented on EW. Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 price target for the company in a research report on Thursday, July 25th. Credit Suisse Group upped their price target on shares of Edwards Lifesciences from $221.00 to $226.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Raymond James upped their price target on shares of Edwards Lifesciences from $200.00 to $232.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. JPMorgan Chase & Co. upped their price target on shares of Edwards Lifesciences from $190.00 to $225.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Finally, Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $210.00 to $228.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 24th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $204.74.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: What is Elliott Wave theory?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit